nach oben

Erschienen in:

Open Access 01.12.2020 | COVID-19 | Letter

An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial

verfasst von: Ilad Alavi Darazam, Firouze Hatami, Mohammad Mahdi Rabiei, Mohamad Amin Pourhoseingholi, Omid Moradi, Shervin Shokouhi, Mohammad Reza Hajesmaeili, Minoosh Shabani, Seyed Sina Naghibi Irvani

Erschienen in: Trials | Ausgabe 1/2020

Titel: An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
verfasst von: Ilad Alavi Darazam
Firouze Hatami
Mohammad Mahdi Rabiei
Mohamad Amin Pourhoseingholi
Omid Moradi
Shervin Shokouhi
Mohammad Reza Hajesmaeili
Minoosh Shabani
Seyed Sina Naghibi Irvani
Publikationsdatum: 01.12.2020
Verlag: BioMed Central
Schlagwort: COVID-19
Erschienen in: Trials / Ausgabe 1/2020
Elektronische ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-020-04812-2

Springer Medizin

Weitere Artikel der Ausgabe 1/2020

Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan

Does asymmetry in patient recruitment in large critical care trials follow the Pareto principle?

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)

Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomised controlled study

Effects of Transcranial Direct Current Stimulation (tDCS) and Approach Bias Modification (ABM) training on food cravings in people taking antipsychotic medication

Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU